Renal amyloidosis Medical Services in China

Renal amyloidosis is a rare, systemic disorder characterized by the extracellular deposition of misfolded amyloid fibrils—primarily immunoglobulin light chains (AL type) or serum amyloid A protein (AA type)—within the kidney’s glomeruli, tubules, and interstitium. These insoluble, beta-pleated sheet aggregates disrupt normal renal architecture and function, leading to progressive proteinuria, nephrotic syndrome, and ultimately end-stage kidney disease if untreated. Pathogenesis hinges on abnormal protein folding and impaired clearance: in AL amyloidosis, clonal plasma cell dyscrasia produces excess monoclonal light chains that aggregate into amyloid; in AA amyloidosis, chronic inflammatory conditions (e.g., rheumatoid arthritis, tuberculosis, or familial Mediterranean fever) drive sustained overproduction of serum amyloid A, which fragments and deposits as amyloid in tissues. Less common forms include hereditary (ATTR, APOL1-related) and dialysis-related (β2-microglobulin) variants. Epidemiologically, renal amyloidosis accounts for ~1–5% of all cases of nephrotic syndrome in adults and is significantly underdiagnosed due to nonspecific early symptoms and reliance on tissue biopsy with Congo red staining and immunohistochemistry or mass spectrometry for definitive subtyping. Incidence is estimated at 5–10 new cases per million population annually in high-income countries; AL amyloidosis peaks in the sixth to seventh decades (median age 63), with a male predominance (M:F ≈ 1.5:1); AA amyloidosis occurs across broader age groups but correlates strongly with duration and severity of underlying inflammation. Key risk factors include monoclonal gammopathy of undetermined significance (MGUS), multiple myeloma, chronic infections (e.g., osteomyelitis, HIV), autoimmune diseases, and genetic predispositions (e.g., SAA1 polymorphisms). Quality of life is profoundly impacted: patients commonly experience debilitating fatigue, edema-related mobility limitations, recurrent infections due to hypoalbuminemia and immunoglobulin loss, thromboembolic events, and psychological distress—including anxiety and depression—stemming from diagnostic delays, treatment complexity, and uncertain prognosis. As renal function declines, dietary restrictions, frequent clinic visits, and eventual dialysis or transplant candidacy further erode autonomy and social participation. Early diagnosis remains critical—not only to preserve kidney function but also to address systemic involvement (e.g., cardiac, hepatic, or neurologic amyloid), which dictates overall survival. Without timely intervention, median survival in AL amyloidosis with renal involvement is <2 years; with modern risk-adapted therapy, 5-year survival now exceeds 60%. Multidisciplinary care involving nephrology, hematology, cardiology, and pathology is essential for optimal outcomes.

Renal amyloidosis is a systemic disorder characterized by the extracellular deposition of insoluble, misfolded fibrillar proteins—amyloid—in the kidney, leading to progressive glomerular and tubulointerstitial injury, proteinuria, nephrotic syndrome, and ultimately end-stage kidney disease. The pathogenesis hinges on abnormal protein folding, aggregation into β-pleated sheet structures resistant to proteolysis, and subsequent tissue infiltration. The specific clinical and pathological features depend critically on the precursor protein involved.

The most common cause of renal amyloidosis is AL (amyloid light-chain) amyloidosis, accounting for ~80–90% of cases with significant renal involvement. It arises from a clonal plasma cell dyscrasia—typically a low-burden, often non-secretory multiple myeloma or monoclonal gammopathy of undetermined significance (MGUS)—that overproduces immunoglobulin light chains (predominantly lambda). These free light chains undergo conformational change, aggregate, and deposit as amyloid in glomeruli (especially mesangium and capillary walls), arterioles, and interstitium. Triggers include chronic antigenic stimulation (e.g., autoimmune disorders, chronic infections), aging-related immune dysregulation, and somatic mutations in immunoglobulin genes that promote amyloidogenicity.

AA (amyloid A) amyloidosis is the second most frequent renal form, particularly in regions with high endemic chronic inflammatory burden. It results from sustained overproduction of serum amyloid A (SAA), an acute-phase reactant synthesized by hepatocytes in response to interleukin-1, IL-6, and TNF-α. Persistent elevation of SAA—due to uncontrolled chronic infections (e.g., tuberculosis, leprosy, osteomyelitis), autoimmune diseases (e.g., rheumatoid arthritis, ankylosing spondylitis, familial Mediterranean fever), or chronic inflammatory bowel disease—leads to proteolytic cleavage and misfolding into AA fibrils. Renal deposition typically follows years of unmitigated inflammation; thus, inadequate control of underlying inflammation is a key modifiable trigger.

Hereditary (ATTRv and non-ATTR) forms constitute a smaller but clinically important subset. Hereditary transthyretin amyloidosis (ATTRv) is autosomal dominant and caused by pathogenic variants in the TTR gene (e.g., Val30Met, Thr60Ala); while predominantly associated with cardiac and neuropathic involvement, renal manifestations—including proteinuria and impaired GFR—occur in up to 20% of patients, especially with certain variants and in older age. Other hereditary types include apolipoprotein AI (APOA1), fibrinogen Aα-chain (FGA), and lysozyme (LYZ) amyloidoses, each linked to specific gain-of-function missense mutations that destabilize the native protein structure and enhance amyloidogenic propensity. Genetic risk factors include family history, specific ethnic predispositions (e.g., Val30Met in Portuguese, Swedish, and Japanese populations; Glu54Lys in African Americans), and compound heterozygosity in rare cases.

Environmental and acquired risk factors are substantial. Chronic kidney disease itself may promote amyloidogenesis via impaired clearance of amyloidogenic precursors. Long-term hemodialysis (>5–10 years) predisposes to β2-microglobulin (Aβ2M) amyloidosis, though this primarily affects joints and bones rather than native kidneys; however, residual renal function in dialysis patients remains vulnerable to coexisting AL or AA deposition. Occupational or geographic exposures contributing to persistent infection or inflammation (e.g., silica dust, endemic mycobacterial exposure) indirectly elevate AA risk. Smoking, obesity, and metabolic syndrome amplify systemic inflammation and oxidative stress, potentially accelerating amyloid deposition and endothelial injury. Advanced age (>60 years) is a consistent epidemiological risk factor across subtypes, reflecting cumulative immune senescence, declining proteostasis, and prolonged exposure to triggers. Male sex confers higher risk for AL and AA amyloidosis, possibly due to hormonal modulation of plasma cell biology and inflammatory responses. Importantly, delayed diagnosis—often stemming from nonspecific early symptoms (fatigue, edema, foamy urine) and under-recognition of proteinuria in elderly or comorbid patients—functions as a critical iatrogenic risk factor for irreversible renal damage. Early tissue diagnosis via renal biopsy with Congo red staining and mass spectrometry-based typing is essential to guide etiology-specific therapy and mitigate progression.

Renal amyloidosis is a systemic disorder characterized by extracellular deposition of insoluble, misfolded fibrillar proteins—predominantly immunoglobulin light chains (AL amyloidosis) or serum amyloid A protein (AA amyloidosis)—within the glomeruli, interstitium, and vasculature of the kidneys. As amyloid accumulates, it disrupts normal renal architecture and function, leading to progressive kidney injury. Early symptoms are often subtle and nonspecific, reflecting subclinical glomerular damage and early podocyte dysfunction. Patients may report mild fatigue, unexplained weight loss, or intermittent peripheral edema—particularly in the lower extremities—without overt hypertension or gross hematuria. Orthostatic lightheadedness or postprandial fullness may occur due to concomitant autonomic involvement in AL amyloidosis, though these are not renal-specific. Urinalysis may reveal isolated microalbuminuria or low-grade proteinuria (<1 g/day), frequently missed without targeted screening. Serum creatinine typically remains within normal limits at this stage, and estimated glomerular filtration rate (eGFR) is preserved; however, sensitive biomarkers such as urinary retinol-binding protein (RBP), alpha-1-microglobulin, or elevated serum cystatin C may signal early tubular stress or glomerular hyperfiltration preceding overt nephrotic syndrome.

Typical symptoms emerge with advancing amyloid burden and correlate with the onset of nephrotic-range proteinuria (>3.5 g/day). The hallmark clinical presentation is the nephrotic syndrome: profound peripheral and periorbital edema, hypoalbuminemia (<30 g/L), hyperlipidemia (elevated total cholesterol, LDL, and triglycerides), and lipiduria (oval fat bodies and fatty casts on urine microscopy). Patients commonly develop refractory edema despite sodium restriction and diuretic therapy due to intravascular volume depletion secondary to hypoalbuminemia-induced reduction in oncotic pressure. Hypertension is paradoxically uncommon in early-to-moderate disease—unlike other glomerulopathies—and may even be absent or masked by autonomic neuropathy; however, it can develop later with interstitial fibrosis or renovascular amyloid infiltration. Microscopic hematuria occurs in ~20–30% of cases, usually without red blood cell casts, distinguishing it from pauci-immune vasculitis or lupus nephritis. Gross hematuria is rare. Renal vein thrombosis may manifest acutely with flank pain, sudden worsening of edema, or new-onset renal insufficiency—especially in patients with severe hypoalbuminemia (<20 g/L) and elevated D-dimer.

Accompanying symptoms reflect systemic amyloid deposition beyond the kidney. In AL amyloidosis, patients frequently exhibit cardiac involvement (e.g., dyspnea on exertion, orthopnea, palpitations, or low-voltage QRS on ECG), hepatomegaly, macroglossia, carpal tunnel syndrome (often bilateral and preceding renal diagnosis), purpura (especially periorbital 'raccoon eyes'), or gastrointestinal manifestations (diarrhea, early satiety, or malabsorption). AA amyloidosis is commonly associated with chronic inflammatory conditions—including rheumatoid arthritis, ankylosing spondylitis, inflammatory bowel disease, or chronic infections (e.g., tuberculosis, osteomyelitis)—and thus presents with persistent fever, night sweats, elevated CRP and SAA levels, and signs of underlying inflammation. Autonomic and peripheral neuropathy (e.g., orthostatic hypotension, gastroparesis, or distal sensory loss) further support AL etiology. Fatigue, anorexia, and unintentional weight loss are nearly universal across subtypes and reflect both chronic disease burden and cytokine-mediated catabolism.

Complications arise from progressive renal failure and systemic amyloid toxicity. End-stage kidney disease (ESKD) develops in up to 40% of AL and 25% of AA patients within 5 years of diagnosis if untreated. Thromboembolic events—including deep vein thrombosis, pulmonary embolism, and renal vein thrombosis—are significantly increased due to urinary antithrombin III loss, platelet dysfunction, and immobility from edema. Infections (e.g., spontaneous bacterial peritonitis, cellulitis, pneumonia) occur with heightened frequency owing to loss of immunoglobulins and complement factors in urine, impaired opsonization, and immunosuppressive therapy. Cardiac amyloidosis—particularly in AL—carries high mortality; arrhythmias (atrial fibrillation, high-grade AV block), restrictive cardiomyopathy, and heart failure often coexist and worsen prognosis. Gastrointestinal amyloid infiltration may cause bleeding, pseudo-obstruction, or protein-losing enteropathy, exacerbating hypoalbuminemia. Rarely, amyloid deposits in adrenal glands lead to secondary adrenal insufficiency, presenting with hyponatremia, hyperkalemia, and hypotension.

Diagnosis requires a high index of suspicion, especially in patients with unexplained nephrotic syndrome, particularly when accompanied by organomegaly, neuropathy, or a known plasma cell dyscrasia or chronic inflammatory disease. Initial evaluation includes quantification of proteinuria (24-hour urine collection or urine protein-to-creatinine ratio), serum albumin, lipid panel, serum free light chains (kappa/lambda ratio), serum immunofixation electrophoresis, and bone marrow biopsy with immunohistochemistry for clonal plasma cells in suspected AL disease. Serum amyloid A (SAA) level helps differentiate AA amyloidosis. Kidney biopsy remains the gold standard: Congo red staining of renal tissue demonstrates apple-green birefringence under polarized light; electron microscopy reveals non-branching, rigid 7–10 nm fibrils. Typing of amyloid is critical and achieved via immunohistochemistry, mass spectrometry-based proteomics (gold standard for specificity), or laser microdissection followed by liquid chromatography-tandem mass spectrometry (LC-MS/MS). Cardiac imaging (echocardiography with strain analysis, cardiac MRI with late gadolinium enhancement, or bone scintigraphy with 99mTc-DPD/PYP/HMDP) is essential for staging AL amyloidosis.

Differential diagnosis includes other causes of nephrotic syndrome: minimal change disease (common in children, steroid-responsive, no systemic features), focal segmental glomerulosclerosis (FSGS; often associated with obesity, HIV, or APOL1 risk variants), membranous nephropathy (anti-PLA2R or anti-THSD7A positive, rarely systemic), diabetic nephropathy (history of diabetes, retinopathy, nodular glomerulosclerosis on biopsy), and lupus nephritis (positive ANA/dsDNA, immune complex deposits, extrarenal manifestations). Unlike amyloidosis, these entities typically lack systemic stigmata (e.g., macroglossia, carpal tunnel, purpura) and show distinct histopathologic patterns—immune complex deposits on immunofluorescence, absence of Congo red positivity, or characteristic ultrastructural findings (e.g., subepithelial spikes in membranous nephropathy). Importantly, AL amyloidosis must be distinguished from monoclonal gammopathy of renal significance (MGRS), which includes light chain proximal tubulopathy or light chain cast nephropathy—conditions that share clonal plasma cell disorders but differ in pathogenesis, histology, and treatment response. Accurate typing prevents inappropriate therapy (e.g., avoiding rituximab monotherapy in AL or delaying anti-inflammatory treatment in AA) and guides prognostication and transplant eligibility.

Renal amyloidosis is a systemic disorder characterized by extracellular deposition of misfolded amyloid fibrils—primarily derived from immunoglobulin light chains (AL amyloidosis) or serum amyloid A protein (AA amyloidosis)—within the glomeruli, interstitium, and vasculature of the kidneys. This leads to progressive proteinuria, nephrotic syndrome, declining glomerular filtration rate (GFR), and ultimately end-stage kidney disease (ESKD) if untreated. Management requires multidisciplinary coordination, with nephrology at its core, and must be tailored to the underlying amyloid type, disease burden, organ involvement, and patient comorbidities.

Conservative treatment forms the essential foundation of care and aims to mitigate complications, preserve residual renal function, and improve quality of life. Strict blood pressure control—targeting <130/80 mmHg—is achieved using renin-angiotensin-aldosterone system (RAAS) inhibitors (e.g., lisinopril, losartan), which reduce intraglomerular hypertension and proteinuria. Diuretic therapy (e.g., furosemide, often combined with spironolactone in resistant edema) addresses volume overload and hypoalbuminemia-related ascites or pleural effusions. Nutritional support includes moderate protein intake (0.8–1.0 g/kg/day) to avoid catabolism without exacerbating proteinuria; sodium restriction (<2 g/day) is critical for edema and hypertension control. Hyperlipidemia is managed with high-intensity statins (e.g., atorvastatin 40–80 mg daily), given the high prevalence of dyslipidemia in nephrotic syndrome. Thromboprophylaxis with low-molecular-weight heparin (e.g., enoxaparin 40 mg SC daily) or direct oral anticoagulants (e.g., apixaban 2.5 mg BID) is indicated in patients with serum albumin <2.5 g/dL and additional risk factors (e.g., immobility, prior thrombosis), due to the hypercoagulable state associated with AL amyloidosis and nephrotic syndrome.

Pharmacologic therapy targets the underlying amyloidogenic precursor. For AL amyloidosis—the most common renal form—first-line treatment is hematologic-directed therapy to suppress clonal plasma cell production of pathogenic light chains. The standard regimen is daratumumab (a human monoclonal anti-CD38 antibody) combined with cyclophosphamide and dexamethasone (D-CyDex), administered intravenously and orally over 6–12 months. This achieves hematologic complete response (CR) in ~60–70% of eligible patients and significantly improves renal outcomes, including stabilization or reduction in proteinuria and slower eGFR decline. Alternative regimens include bortezomib-based combinations (e.g., CyBorD: cyclophosphamide, bortezomib, dexamethasone), particularly in patients with cardiac involvement or neuropathy. For AA amyloidosis—often secondary to chronic inflammatory conditions such as rheumatoid arthritis, ankylosing spondylitis, or familial Mediterranean fever—treatment focuses on controlling the underlying inflammation. Biologic agents like IL-1 inhibitors (e.g., anakinra, canakinumab) or TNF-alpha antagonists (e.g., infliximab, adalimumab) are used to suppress serum amyloid A (SAA) synthesis; sustained SAA levels <10 mg/L correlate strongly with renal amyloid regression and improved survival. In hereditary forms (e.g., ATTR amyloidosis), tafamidis—a transthyretin stabilizer—may be considered off-label in select cases, though renal involvement is less common than in cardiac or neurologic variants.

Surgical treatment has a limited but defined role. Kidney transplantation is feasible in selected patients with AL amyloidosis only after achieving deep and sustained hematologic remission (≥12 months CR confirmed by bone marrow biopsy and serum free light chain ratio normalization), absence of significant cardiac or gastrointestinal involvement, and stable organ function. Graft survival is comparable to non-amyloid recipients when strict eligibility criteria are met, with 5-year graft survival exceeding 80%. Recurrence of AL amyloid in the allograft occurs in <5% of rigorously selected cases. For AA amyloidosis, transplantation is more readily considered once the underlying inflammatory disease is controlled, with lower recurrence rates (<10%). Autologous stem cell transplantation (ASCT) remains an option for fit, younger patients (<65 years) with AL amyloidosis and adequate cardiac reserve (NT-proBNP <3,300 ng/L, troponin T <0.06 ng/mL); however, its use has declined with the advent of highly effective daratumumab-based regimens due to higher toxicity and mortality risks.

China offers distinct advantages in the management of renal amyloidosis. First, integrated national amyloidosis referral networks—centered at tertiary hospitals such as Peking University First Hospital, Shanghai Renji Hospital, and West China Hospital—provide rapid access to specialized diagnostics, including mass spectrometry-based amyloid typing (gold standard), cardiac MRI with late gadolinium enhancement, and abdominal fat pad biopsy with Congo red staining. Second, China’s robust pharmaceutical regulatory framework has accelerated approval of novel agents: daratumumab received NMPA approval for AL amyloidosis in 2022, and biosimilar versions have improved affordability and accessibility across provincial healthcare systems. Third, real-world evidence from large Chinese cohorts (e.g., the China Amyloidosis Registry) informs region-specific treatment algorithms, particularly regarding optimal dosing in patients with reduced kidney function and managing drug-induced cytopenias in Asian populations. Fourth, multidisciplinary amyloid clinics—staffed by nephrologists, hematologists, cardiologists, and genetic counselors—offer coordinated longitudinal follow-up, reducing diagnostic delays that historically averaged >18 months globally but now average <6 months in top-tier centers.

Recovery and long-term monitoring require structured, patient-centered guidance. Patients should undergo quarterly assessments including 24-hour urine protein, serum creatinine/eGFR, albumin, free light chains (kappa/lambda ratio), and NT-proBNP. Annual echocardiography and nerve conduction studies are recommended for AL patients. Lifestyle modifications include smoking cessation, influenza/pneumococcal vaccination, and avoidance of NSAIDs and iodinated contrast media. Psychological support is integral—depression and anxiety affect >40% of amyloidosis patients—and many Chinese centers now embed clinical psychologists within amyloid clinics. Dietary counseling emphasizes plant-based proteins, omega-3 fatty acids, and potassium restriction if hyperkalemic. Finally, patients must understand that renal amyloidosis is a chronic condition requiring lifelong surveillance: even in hematologic remission, late-onset renal deterioration may occur due to irreversible structural damage, underscoring the importance of early diagnosis and sustained therapeutic adherence. With timely, precise, and integrated care, many patients achieve prolonged renal stability, preserved independence, and meaningful survival extension.